Chinese researchers develop immunotherapeutic agent for colon cancer
Release time:2024-05-21 14:46:38
TIANJIN, March 15 (Xinhua) -- Chinese researchers have developed a novel immunotherapeutic agent for 。
TIANJIN, March 15 (Xinhua) -- Chinese researchers have developed a novel immunotherapeutic agent for treating colon cancer, according to a recent article in the academic journal ACS Nano. In animal experiments, the agent, upon successful entry into tumor cells, can enhance T cell effector function to kill tumor cells and suppress colon tumor growth, according to Lu Chunwan from the School of Life Sciences of Tianjin University, one of the authors of the article. The agent can enhance tumor immunogenicity and inhibit colon tumor growth, with no significant impact on normal cells, said Lu. Colon cancer, characterized by its long latency period and high mortality rate, poses a severe threat to human health. Among various therapies, immunotherapy is considered one of the most promising treatment directions, according to Lu.
(Editor:Fu Bo)
Related articles
Candice Swanepoel stuns in a form
Candice Swanepoel looked incredible as she arrived at the 77th annual Cannes Film Festival premiere2024-05-21Commentary: Hidden agenda behind hype of China's overcapacity problem
(Xinhua) 13:04, April 02, 2024Robots weld bodyshells of cars at a workshop of Chinese electric vehic2024-05-21Bazaar train boosts incomes for residents in Xinjiang, NW China
(People's Daily Online) 13:39, April 11, 2024Attending bazaars has been a longstanding tradition in2024-05-21UK's medical regulator says sorry for striking off gay doctors before 1966
Britain decriminalised sex between men in England and Wales in 1967. File photo. Photo: Wikimedia2024-05-21Lynn Williams breaks NWSL goal
Lynn Williams scored her 79th league goal, becoming the National Women’s Soccer League all-time scor2024-05-21China, Vietnam hold 8th border defense friendship exchange
KUNMING, April 12 (Xinhua) -- China and Vietnam held the eighth border defense friendship exchange f2024-05-21
atest comment